Co-Diagnostics, Inc.

NasdaqCM:CODX Stock Report

Market Cap: US$36.9m

Co-Diagnostics Past Earnings Performance

Past criteria checks 0/6

Co-Diagnostics's earnings have been declining at an average annual rate of -18.2%, while the Medical Equipment industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 14.8% per year.

Key information

-18.2%

Earnings growth rate

-12.1%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate14.8%
Return on equity-41.1%
Net Margin-518.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

May 18
One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Apr 14
A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Co-Diagnostics: Hold Thesis Remains Well Intact

Sep 07

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Aug 11

Co-Diagnostics spikes on shipments of monkeypox test

Jul 11

Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Jul 06
Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant

Jun 21

Co-Diagnostics: Where's Eikon?

Apr 03

Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 28
Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Co-Diagnostics: Swinging For The Fences

Jan 24

Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?

Dec 28
Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?

Why Co-Diagnostics Is A Solid Covid-19 Play

Aug 19

Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Aug 14
Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Co-Diagnostics gets CE marking for direct saliva SARS-CoV-2 test

Jun 18

Co-Diagnostics: No One-Hit Wonder

Jun 04

This Just In: Analysts Are Boosting Their Co-Diagnostics, Inc. (NASDAQ:CODX) Outlook for This Year

May 18
This Just In: Analysts Are Boosting Their Co-Diagnostics, Inc. (NASDAQ:CODX) Outlook for This Year

These Analysts Just Made A Huge Downgrade To Their Co-Diagnostics, Inc. (NASDAQ:CODX) EPS Forecasts

Mar 30
These Analysts Just Made A Huge Downgrade To Their Co-Diagnostics, Inc. (NASDAQ:CODX) EPS Forecasts

US$22.33: That's What Analysts Think Co-Diagnostics, Inc. (NASDAQ:CODX) Is Worth After Its Latest Results

Mar 27
US$22.33: That's What Analysts Think Co-Diagnostics, Inc. (NASDAQ:CODX) Is Worth After Its Latest Results

Revenue & Expenses Breakdown
Beta

How Co-Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CODX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 237-352123
30 Sep 235-432222
30 Jun 237-382221
31 Mar 2312-322119
31 Dec 2234-142217
30 Sep 2253152015
30 Jun 2278282216
31 Mar 22101402617
31 Dec 2198372515
30 Sep 21105422514
30 Jun 219646219
31 Mar 219351155
31 Dec 207542133
30 Sep 20482892
30 Jun 20261072
31 Mar 202-651
31 Dec 190-651
30 Sep 190-651
30 Jun 190-651
31 Mar 190-651
31 Dec 180-651
30 Sep 180-651
30 Jun 180-851
31 Mar 180-841
31 Dec 170-741
30 Sep 170-631
30 Jun 170-311
31 Mar 170-211
31 Dec 160-211
30 Sep 160-211
31 Dec 150-211

Quality Earnings: CODX is currently unprofitable.

Growing Profit Margin: CODX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CODX is unprofitable, and losses have increased over the past 5 years at a rate of 18.2% per year.

Accelerating Growth: Unable to compare CODX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CODX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.7%).


Return on Equity

High ROE: CODX has a negative Return on Equity (-41.08%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.